[Form 4] CATALYST PHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Catalyst Pharmaceuticals, Inc. (CPRX) reported insider equity activity for its Chief Commercial Officer on a Form 4. On 11/21/2025, the officer exercised 5,603 shares of common stock and had 1,641 shares withheld to cover taxes, leaving 3,962 common shares beneficially owned directly. The filing also shows a grant on 11/20/2025 of options to purchase 106,873 shares of common stock at an exercise price of $22.77, vesting in three equal annual installments on November 20, 2026, 2027 and 2028. In addition, the officer received 32,257 restricted stock units tied to common stock, and RSUs covering 5,603 shares were settled into stock on 11/21/2025. Following these transactions, the officer holds 1,064,535 derivative securities, including options and RSUs, all reported as directly owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Del Carmen Jeffrey

(Last) (First) (Middle)

355 ALHAMBRA CIRCLE

SUITE 801

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	11/21/2025		M		5,603	A	(1)	5,603	D
Common Stock, par value $0.001 per share	11/21/2025		F		1,641	D	(2)	3,962	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	$22.77	11/20/2025		A		106,873		(3)	11/20/2032	Common Stock	106,873	$0	1,037,881	D
Restricted Stock Units	(4)	11/20/2025		A		32,257		(3)	(4)	Common Stock	32,257	$0	1,070,138	D
Restricted Stock Units	(4)	11/21/2025		M			5,603	(5)	(6)	Common Stock	5,603	$0	1,064,535	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

2. Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.

3. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.

4. Shares of common stock will be delivered to the Reporting Person upon vesting.

5. Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.

6. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.

	/s/ Jeffrey Del Carmen	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Catalyst Pharmaceuticals (CPRX) report?

The company reported on Form 4 that its Chief Commercial Officer exercised 5,603 shares of common stock on 11/21/2025 and had 1,641 shares withheld to cover taxes, resulting in 3,962 common shares beneficially owned directly afterward.

What new stock options were granted to the Catalyst Pharmaceuticals (CPRX) executive?

The Chief Commercial Officer was granted options on 11/20/2025 to purchase 106,873 shares of Catalyst Pharmaceuticals common stock at an exercise price of $22.77 per share. These options vest in three equal tranches on November 20, 2026, 2027 and 2028.

How many restricted stock units (RSUs) were awarded in this Catalyst Pharmaceuticals (CPRX) filing?

The filing shows an award of 32,257 restricted stock units on 11/20/2025, each representing the right to receive one share of common stock upon vesting. RSUs covering 5,603 shares were settled into common stock on 11/21/2025.

What is the vesting schedule for the options and RSUs in the Catalyst Pharmaceuticals (CPRX) Form 4?

The options and related RSUs granted on 11/20/2025 vest in equal one-third tranches on November 20, 2026, November 20, 2027 and November 20, 2028. Additional RSUs tied to 5,603 shares vest in equal one-third tranches on November 21, 2025, 2026 and 2027, with shares to be delivered within sixty days of each vesting date.

How many derivative securities does the Catalyst Pharmaceuticals (CPRX) officer hold after these transactions?

After the reported grants and exercises, the Chief Commercial Officer holds 1,064,535 derivative securities, consisting of options and restricted stock units linked to Catalyst Pharmaceuticals common stock, all listed as directly owned.

What is the role of the reporting person in Catalyst Pharmaceuticals (CPRX)?

The reporting person in this Form 4 is an officer of Catalyst Pharmaceuticals, serving as the company's Chief Commercial Officer, and the filing reports his beneficial ownership and recent equity awards.